Home | Welcome to Contract Pharma   
Last Updated Friday, September 19 2014
Print

Financial Report: Bristol-Myers Squibb



Published April 26, 2013
Bristol-Myers Squibb

1Q Revenues: $3.8 billion (-27%)
 
1Q Earnings: $623 million (-58%)
 
Comments: Revenues were pounded by patent expiration for Avapro/Avalide (-78%) in March 2012 and Plavix (-95%) in May 2012. U.S. sales decreased 44% to $2.0 billion. International net sales increased 6% to $1.9 billion. Baraclude sales were up 13% to $366 million. Erbitux sales were down 9% to $162 million. Sprycel sales were up 24% to $287 million. Yervoy sales were up 49% to 229 million. Abilify sales were down 16% to 52 million. Orencia sales were up 26% to $320 million. R&D expenses increased 2% to $930 million in the quarter.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On